Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging.
about
The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.The hallmarks of premalignant conditions: a molecular basis for cancer preventionImpact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancerComparison of methods using paraffin-embedded tissues and exfoliated cervical cells to evaluate human papillomavirus genotype attributionGenetic and Environmental Factors in Invasive Cervical Cancer: Design and Methods of a Classical Twin Study.Current status and future prospects for human papillomavirus vaccines.Maximizing the Impact of Human Papillomavirus Vaccination.Control of HPV-associated cancers with HPV vaccination.Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States.Development of World Health Organization (WHO) recommendations for appropriate clinical trial endpoints for next-generation Human Papillomavirus (HPV) vaccines.
P2860
Q30251408-A027B3F0-4EFE-4F50-9066-ED08F9A3D52AQ34507291-C48549E4-4A6F-4B78-A925-A8EFE5A7FD48Q36679858-C3DE35A3-7811-409F-B8C2-A06F34A0AB76Q36964366-01CEDF6F-E1FF-4086-97AE-D97D6569F7D9Q37130168-2B9D8F14-2EB5-4417-8A0C-0F61CF94F5DAQ37135163-5402B6E5-A9DB-452C-9ECF-454E88E6459DQ37375242-AD6C786F-749A-4512-A1C3-C03BF77F7B4DQ38376969-8FE16269-30F4-4F5C-AA1A-468F62059694Q40056541-ADB8708C-98FB-4690-BDA3-7082B378678EQ40207559-66618FFC-1BD3-4463-860F-94C4976D28A7Q40709573-22556416-56F1-4272-80CB-AE85D976BC24Q47572082-C8B7C385-2A5D-4DCE-9097-AFE315B39050Q50091394-AA66AD46-B995-4207-90F0-12295614F4E3
P2860
Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Primary endpoints for future p ...... infection and immunobridging.
@en
type
label
Primary endpoints for future p ...... infection and immunobridging.
@en
prefLabel
Primary endpoints for future p ...... infection and immunobridging.
@en
P2093
P1433
P1476
Primary endpoints for future p ...... infection and immunobridging.
@en
P2093
Allan Hildesheim
Douglas R Lowy
Participants in the IARC/NCI w ...... rophylactic HPV Vaccine Trials
Rolando Herrero
P304
P356
10.1016/S1470-2045(15)70075-6
P577
2015-05-01T00:00:00Z